Public Citizen Takes Aim At Crestor DTC Ads Defending Statin's Safety
This article was originally published in The Pink Sheet Daily
Executive Summary
AstraZeneca's newspaper ads and website contain "false and/or misleading statements about the FDA's current opinion about Crestor," Public Citizen says in letter to Acting Commissioner Crawford. Agency is urged to stop the company's advertising campaign.
You may also be interested in...
Crestor Safety Defense Misrepresents FDA Position, Agency Tells Company
An AstraZeneca “patient safety” print ad that ran in mid-November “misleadingly suggests that the agency does not believe that Crestor poses safety concerns,” the FDA ad division says in an “untitled” letter to the company. The Crestor ad asserted FDA has concluded safety concerns about rosuvastatin “have no medical or scientific basis.”
Crestor Safety Defense Misrepresents FDA Position, Agency Tells Company
An AstraZeneca “patient safety” print ad that ran in mid-November “misleadingly suggests that the agency does not believe that Crestor poses safety concerns,” the FDA ad division says in an “untitled” letter to the company. The Crestor ad asserted FDA has concluded safety concerns about rosuvastatin “have no medical or scientific basis.”
AstraZeneca Refocuses On Risk Management, Elevates Development Oversight
Former Exec VP-Product Strategy & Licensing John Patterson will assume the board-level position of exec director-development effective Jan. 1. Regulatory affairs overhaul will include a review of ongoing Phase III programs for Galida, Cerovive and Symbicort.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: